When the Mylan pharmaceutical giant raised the price of EpiPens by nearly 500%, it created a major controversy. Heather Bresch, CEO of Mylan said that the controversy created by her company has ‘opened a window into a broken system.’
The head of the pharmaceutical giant Mylan is speaking out about the firestorm created by the nearly-500 percent increase in the price of EpiPens.
Mylan CEO Heather Bresch was called to testify before Congress last year about the huge price increase for the life-saving allergy medicine to $600. After the controversy, the company cut the list price of generic EpiPens to $300.
In an interview with “CBS This Morning” co-host Norah O’Donnell, Bresch said bigger change is needed to fix what she calls a broken healthcare system.
“You took it on the chin this summer. Before Congress and in the public,” O’Donnell said.